[Study on the rationale for chemotherapy of refractory choriocarcinoma]

The combination chemotherapy consisting of methotrexate (MTX), actinomycin D (ACD), and an alkylating agent was applied to the high risk patients refractory to MTX and/or ACD. The remission rate of the high risk group was about 70% and that of low risk patients was 100%. It is important to seek an effective chemotherapy for patients refractory to the above combined chemotherapy; therefore, we tried out the following regimens: (1) Quadritherapy with MTX, ACD, CPM and vincristine; (2) CHAMOMA protocol; (3) cis-platinum, bleomycin and vinblastine therapy; (4) ultra high dose MTX therapy and (5) the combination chemotherapy without MTX. The last regimen was designed based on the experimental data chemotherapy using nude mice.